Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan;38(1):10–38. doi: 10.2337/cd20-as01

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the American Diabetes Association.

Readers may use this work as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://www.diabetesjournals.org/content/license for details. Readers may link to the version of record of this work on professional.diabetes.org/standards, but ADA permission is required to post this work on any third-party website or platform. Requests to reuse or repurpose; adapt or modify; or post, display, or distribute this work may be sent to permissions@diabetes.org.

PMC Copyright notice

FIGURE 9.2 — Intensifying to injectable therapies. FPG, fasting plasma glucose; FRC, fixed-ratio combination; GLP-1 RA, GLP-1 receptor agonist; iDegLira, insulin degludec/liraglutide; iGlarLixi, insulin glargine/lixisenatide; max, maximum; PPG, postprandial glucose; Table 9.3 appears in the complete 2020 Standards of Care. Adapted from Davies MJ, D'Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701.